PE20140890A1 - Derivados de isoxazolidina - Google Patents

Derivados de isoxazolidina

Info

Publication number
PE20140890A1
PE20140890A1 PE2013002015A PE2013002015A PE20140890A1 PE 20140890 A1 PE20140890 A1 PE 20140890A1 PE 2013002015 A PE2013002015 A PE 2013002015A PE 2013002015 A PE2013002015 A PE 2013002015A PE 20140890 A1 PE20140890 A1 PE 20140890A1
Authority
PE
Peru
Prior art keywords
halogen
hydroxy
dimethyl
independently
refers
Prior art date
Application number
PE2013002015A
Other languages
English (en)
Inventor
Eleonora Ghidini
Andrea Rizzi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20140890A1 publication Critical patent/PE20140890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES (CH2)n-Z-(CH2)n�-R3, DONDE n Y n� SON INDEPENDIENTEMENTE 0, 1 O 2; Z ES UNA UNION SIMPLE O SE SELECCIONA ENTRE S, O, Y OC(R4R5), R3 ES H, HALOGENO, CN, OH, ENTRE OTROS; R2 ES (C1-C8)ALQUILO LINEAL O RAMIFICADO, (C1-C6)ALCOXI, (C1-C6)HALOALQUILO OPCIONALMENTE SUSTITUIDO CON UNO O MAS GRUPOS CN O ATOMOS DE HALOGENO, ENTRE OTROS; X E Y SON INDEPENDIENTEMENTE H O HALOGENO, CON LA CONDICION QUE CUANDO R1 ES UN GRUPO CH2OH Y R2 ES (C1-C6)ALQUILO O (C3-C8)CICLOALQUILO, LUEGO X E Y SON ATOMOS DE FLUOR. ES UN COMPUESTO PREFERIDO: (4aS,4bR,5S,6aS,6bR,9aS,10aS,10bS,12S)-8-(3,3-DIMETIL-BUTIL)-4b,12-DIFLUORO-5-HIDROXI-6b-(2-HIDROXI-ACETIL)-4a,6a-DIMETIL-4a,4b,5,6,6a,6b,8,9,9a,10,10a,10b,11,12-TETRADECAHIDRO-7-OXA-8-AZA-PENTALEN[2,1-a]FENANTREN-2-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA
PE2013002015A 2011-03-15 2012-03-14 Derivados de isoxazolidina PE20140890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158230 2011-03-15

Publications (1)

Publication Number Publication Date
PE20140890A1 true PE20140890A1 (es) 2014-08-05

Family

ID=44351355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002015A PE20140890A1 (es) 2011-03-15 2012-03-14 Derivados de isoxazolidina

Country Status (22)

Country Link
US (3) US20120234316A1 (es)
EP (2) EP2716648B1 (es)
JP (1) JP6053700B2 (es)
KR (1) KR101956937B1 (es)
CN (1) CN103391945B (es)
AR (1) AR085817A1 (es)
AU (1) AU2012228334B2 (es)
BR (1) BR112013023539B1 (es)
CA (1) CA2850081C (es)
CL (1) CL2013002629A1 (es)
EA (1) EA028904B1 (es)
GE (1) GEP201606566B (es)
IL (1) IL228382A (es)
MX (1) MX345400B (es)
MY (1) MY194140A (es)
PE (1) PE20140890A1 (es)
SG (1) SG193262A1 (es)
TN (1) TN2013000313A1 (es)
TW (1) TWI658047B (es)
UA (1) UA113508C2 (es)
WO (1) WO2012123482A2 (es)
ZA (2) ZA201306881B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140042886A (ko) 2011-08-01 2014-04-07 키에시 파르마슈티시 엣스. 피. 에이. 피롤리딘 고리를 갖는 16,17 위치에서 응축된 항염증용 스테로이드
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
EP2902382A1 (en) * 2014-01-30 2015-08-05 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Primary hydroxylamines and uses thereof
PT3125898T (pt) * 2014-03-31 2020-04-01 Scripps Research Inst Farmacóforo para indução de trail
PT3188759T (pt) 2014-09-03 2020-07-02 Rhizen Pharmaceuticals S A Método de tratamento e composições que compreende um inibidor duplo da quinase pi3k delta-gama e um corticosteroide
CN104262440B (zh) * 2014-09-10 2016-08-17 江西赣亮医药原料有限公司 一种16ɑ-羟基泼尼松龙的制备方法
CN118638008A (zh) * 2024-08-14 2024-09-13 淄博飞源化工有限公司 甲基丙烯酸三氟乙酯及其合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31997A (en) * 1968-05-03 1974-03-14 Lepetit Spa Process for the preparation of pregnano(17alpha,16alpha-d)oxazolines and 16alpha,21-dihydroxy-17alpha-aminopregnanes
US4018774A (en) 1976-02-13 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal [16α,17-d]isoxazolidines
AR224124A1 (es) * 1978-04-05 1981-10-30 Syntex Inc Procedimiento para preparar 4-halo-pregna-1,4-dieno-3,20-dionas
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0415747D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008526776A (ja) 2005-01-03 2008-07-24 ミリアド ジェネティクス， インコーポレイテッド 脳癌の治療の方法
DK2225256T3 (da) * 2007-11-30 2013-03-11 Pfizer Ltd Nye glucocorticoidreceptoragonister
MX2010009022A (es) * 2008-02-27 2010-09-07 Astrazeneca Ab Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
CN101926805A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 一种含有16,17异恶唑烷类甾体化合物的药物组合物
CN102482318B (zh) * 2009-09-11 2015-11-25 奇斯药制品公司 异噁唑烷衍生物
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
KR20140039161A (ko) 2011-03-15 2014-04-01 키에시 파르마슈티시 엣스. 피. 에이. 이소옥사졸리딘 유도체
KR20140042886A (ko) 2011-08-01 2014-04-07 키에시 파르마슈티시 엣스. 피. 에이. 피롤리딘 고리를 갖는 16,17 위치에서 응축된 항염증용 스테로이드
US9155747B2 (en) 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Also Published As

Publication number Publication date
WO2012123482A2 (en) 2012-09-20
US9845337B2 (en) 2017-12-19
EA028904B1 (ru) 2018-01-31
JP2014508181A (ja) 2014-04-03
EA201391173A1 (ru) 2014-01-30
IL228382A0 (en) 2013-12-31
US20180066010A1 (en) 2018-03-08
SG193262A1 (en) 2013-10-30
WO2012123482A3 (en) 2013-02-07
KR20140006016A (ko) 2014-01-15
AR085817A1 (es) 2013-10-30
KR101956937B1 (ko) 2019-03-11
TWI658047B (zh) 2019-05-01
GEP201606566B (en) 2016-11-10
US20150057257A1 (en) 2015-02-26
CA2850081C (en) 2020-01-07
CN103391945B (zh) 2016-11-09
AU2012228334A1 (en) 2013-10-03
BR112013023539B1 (pt) 2022-03-03
JP6053700B2 (ja) 2016-12-27
MX2013010354A (es) 2013-12-06
EP2716648A1 (en) 2014-04-09
EP2716648B1 (en) 2017-06-14
TN2013000313A1 (en) 2015-01-20
ZA201405681B (en) 2015-12-23
MX345400B (es) 2017-01-30
IL228382A (en) 2017-08-31
CN103391945A (zh) 2013-11-13
US20120234316A1 (en) 2012-09-20
CL2013002629A1 (es) 2014-01-10
US10280193B2 (en) 2019-05-07
CA2850081A1 (en) 2012-09-20
UA113508C2 (xx) 2017-02-10
NZ615423A (en) 2015-08-28
BR112013023539A2 (pt) 2017-01-24
EP2686332A2 (en) 2014-01-22
TW201247697A (en) 2012-12-01
MY194140A (en) 2022-11-14
ZA201306881B (en) 2014-11-26
AU2012228334B2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
PE20140890A1 (es) Derivados de isoxazolidina
AR122552A2 (es) Composición acuosa de inmunoglobulina estable durante el almacenamiento y método para estabilizar una composición de inmunoglobulina
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
DOP2016000045A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
SV2016005229A (es) Inhibidores de syk
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
BR112015015031A2 (pt) processo de glicoconjugação
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
BR112015005891A2 (pt) método de sintetizar análogos do hormônio da tireoide e polimorfos destes
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
BR112014015935A8 (pt) composição de agentes de detecção de células tumorais epiteliais e seu método de preparação
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
PE20151995A1 (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
AR087217A1 (es) Sistema de inyeccion de una suspension de cacomicronizada para la remineralizacion del agua desalinizada y dulce
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
PE20120894A1 (es) Derivados de isoxazolidina
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
CL2017002060A1 (es) Compuestos de benzoxaborol y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration